{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T05:23:56Z","timestamp":1739251436365,"version":"3.37.0"},"reference-count":53,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In the CONPET study, multiple myeloma patients with abnormal 18FDG positron emission\/computed tomography scan after upfront autologous stem cell transplantation were treated with four cycles of carfilzomib\u2013lenalidomide\u2013dexamethasone (KRd). Side effect registrations show that carfilzomib might cause dyspnea, cough, respiratory tract infections, and heart failure. The aims were to investigate patient\u2010reported shortness of breath and dyspnea during KRd consolidation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To assess shortness of breath, patients completed the Functional Assessment of Cancer Therapy\u2014Pulmonary Symptom Index (FACT\u2010PSI) and the EORTC QLQ\u2010C30 to assess dyspnea. Shortness of breath was defined as decrease in FACT\u2010PSI score <jats:italic>or<\/jats:italic> starting\/increasing diuretic drugs. Mixed effect logistic regression was used for the effect analysis. Linear mixed model and clinical relevance were used to investigate dyspnea.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 50 patients were included, median age 62\u2009years (interquartile range 54\u201367). 17% reported shortness of breath at Day 15 Cycles 1\u20134 versus 11% at Day 1\u2009Cycles 2\u20134, Cycle 4\u2009Day 29, and 1\u2009month posttreatment (<jats:italic>p<\/jats:italic>\u2010value 0.048). Compared with baseline, patients reported significant, and clinically relevant worsening in dyspnea during consolidation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study confirmed earlier findings of carfilzomib causing shortness of breath during KRd administration and revealed dyspnea during consolidation compared to baseline.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>\n<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">Clinicaltrials.gov<\/jats:ext-link>: NCT03314636, EudraCT: 2017\u2013000586\u201072<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.14358","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T02:00:37Z","timestamp":1733450437000},"page":"517-527","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Health\u2010Related Quality of Life During Carfilzomib\u2013Lenalidomide\u2013Dexamethasone Consolidation: Findings From the Multiple Myeloma <scp>CONPET<\/scp> Study"],"prefix":"10.1111","volume":"114","author":[{"given":"Tine","family":"Rosenberg","sequence":"first","affiliation":[{"name":"Quality of Life Research Center, Department of Haematology Odense University Hospital  Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f6ren","family":"M\u00f6ller","sequence":"additional","affiliation":[{"name":"OPEN, Open Patient Data Explorative Network Odense University Hospital  Odense Denmark"},{"name":"Department of Clinical Research University of Southern Denmark  Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Abildgaard","sequence":"additional","affiliation":[{"name":"Quality of Life Research Center, Department of Haematology Odense University Hospital  Odense Denmark"},{"name":"Department of Clinical Research University of Southern Denmark  Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob Nordberg","family":"N\u00f8rgaard","sequence":"additional","affiliation":[{"name":"Oslo Myeloma Center, Department of Haematology Oslo University Hospital  Oslo Norway"},{"name":"Institute of Clinical Medicine University of Oslo  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Lys\u00e9n","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine University of Oslo  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galina","family":"Tsykonova","sequence":"additional","affiliation":[{"name":"Haukeland University Hospital  Bergen Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Joao","sequence":"additional","affiliation":[{"name":"NOVA Medical School Nova University of Lisbon and Department of Hematology and Myeloma Lymphoma Research Group Champalimaud Foundation  Lisbon Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2131-731X","authenticated-orcid":false,"given":"Annette","family":"Vangsted","sequence":"additional","affiliation":[{"name":"Department of Haematology Copenhagen University Hospital  Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1096-0569","authenticated-orcid":false,"given":"Fredrik","family":"Schjesvold","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine University of Oslo  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2083-3870","authenticated-orcid":false,"given":"Lene Kongsgaard","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Quality of Life Research Center, Department of Haematology Odense University Hospital  Odense Denmark"},{"name":"Department of Clinical Research University of Southern Denmark  Odense Denmark"},{"name":"Section of Haematology, Department of Internal Medicine G\u00f8dstrup Hospital  Herning Denmark"},{"name":"Department of Clinical Medicine Aarhus University  Aarhus Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-078022"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.183475"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13585"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06854.x"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1548-y"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004131"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.177139"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007052"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-425934"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00464-7"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30452-6"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4519"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.735466"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0181-0"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.03.011"},{"key":"e_1_2_11_18_1","unstructured":"US Department of Health and Human Services Food and Drug AdministrationandUS Food and Drug Administration \u201cGuidance for Industry: Patient\u2010Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims \u201dhttps:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM193282.pdf."},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.9334"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-016-2335-9"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.3.608"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01998-7"},{"key":"e_1_2_11_23_1","unstructured":"H.Eshoj L.Nielsen N.Abildgaard andF.Schjesvold \u201cSub\u2010Protocol for Assessing Patient Reported Outcomes and Quality of Life in the CONPET Study \u201dhttps:\/\/findresearcher.sdu.dk\/ws\/portalfiles\/portal\/135962813\/CONPET_PRO_QoL_Protocol_FINAL.pdf2018."},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.352889.x"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.02.012"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-017-1626-1"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-2927-8"},{"key":"e_1_2_11_29_1","first-page":"503","article-title":"Chemotherapy\u2010Induced Neuropathy Among Multiple Myeloma Patients and the Influence of Chemotherapeutic Agents: Results From the Population\u2010Based Profiles Study","volume":"100","author":"Beijers A.","year":"2015","journal-title":"Haematologica"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-3032-y"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04356-0"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2012.07.001"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"volume-title":"The EORTC QLQ\u2010C30 Scoring Manual","year":"2001","author":"Fayers P.","key":"e_1_2_11_34_1"},{"key":"e_1_2_11_35_1","unstructured":"FACIT.org \u201cFunctional Assessment of Cancer Therapy\u2014Pulmonary Symptom Index (FACT\u2010PSI) \u201dhttps:\/\/www.facit.org\/measures\/FACT\u2010PSI."},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-84702-9_6"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136\u2010024\u201003788\u20109"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-023-03366-5"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-022-03200-4"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-022-03181-4"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1385\/MO:18:1:65"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.05.002"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.5137"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2005.07.008"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.02.059"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(99)00071-2"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.0107"},{"key":"e_1_2_11_48_1","unstructured":"EMA \u201cICH E9 (R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials 2021 \u201dhttps:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/ich\u2010e9\u2010r1\u2010addendum\u2010estimands\u2010and\u2010sensitivity\u2010analysis\u2010clinical\u2010trials\u2010guideline\u2010statistical\u2010principles\u2010clinical\u2010trials\u2010step\u20105_en.pdf."},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.4012"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12882"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16889"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402551"},{"key":"e_1_2_11_53_1","unstructured":"National Cancer Institute \u201cCommon Terminology Criteria for Adverse Events (CTCAE) Version 5.0 ed \u201dhttps:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-024-03707-y"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14358","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T03:02:38Z","timestamp":1739242958000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1111\/ejh.14358"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14358","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"type":"print","value":"0902-4441"},{"type":"electronic","value":"1600-0609"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"2024-08-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}